Concord Biotech Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹278Cr
- +13.9% YoY
- +12.6% QoQ
- Net profit
- ₹68Cr
- −8.1% YoY
- +7.9% QoQ
- Margin
- 37%
- −3 pp YoY
- 0 pp QoQ
Guidance rank: #74 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
FY '26 growth expected below historical averages due to first-half challenges; optimistic for Q4 improvement. FY '26 growth expected below historical averages due to H1 challenges but Q3 & Q4 show improving momentum.
From Concord Biotech Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY '26 growth expected below historical averages due to first-half challenges; optimistic for Q4 improvement.
- Medium-term growth drivers include:
- Injectables contributing around 6% growth over the next 3-5 years.
- CDMO segment growth due to global shift favoring India.
- Combined baseline growth (API and formulations) around 18%, with injectables and CDMO potentially raising CAGR to ~25% over time.
- Expansion plans involve new product launches, increasing market share in anti-infectives, antifungal, and oncology segments.
- Non-immunosuppressant products expected to gain market share gradually, similar to immunosuppressants, focusing on complex, niche products with limited competition.
- Moderate volume-led growth in API business; pricing remains stable, with limited discounts.
2 more points from Concord Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Concord Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Additional capex beyond maintenance is being incurred for newer projects linked to customer opportunities and growth, contributing to a blended capex of INR 100-150 crores annually.
- The company is investing in commercialization of new injectable facilities and subsidiaries in the U.S. market, with the injectable facility having a peak revenue potential of approximately INR 600 crores.
- Concord Lifegen Limited, a wholly owned subsidiary, was incorporated to strengthen marketing, sales, and distribution in India.
2 more points from Concord Biotech Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Concord Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- It mentions increased engagement and advanced discussions around second source supply opportunities post-clarity on U.S. tariffs, indicating a growing pipeline of potential orders.
- Discussions are underway with both existing customers and new innovator/generic players, with expectations of commercializing at least one new project in the near term.
- The company is optimistic about growth momentum entering Q4 FY '26 and expects improved performance driven by new product launches and CDMO partnerships.
- There is ongoing evaluation of both organic and inorganic options for utilizing cash flow to capture future growth opportunities.
Concord Biotech Ltd — Quarterly revenue & net profit
Concord Biotech Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 278 | 244 | +13.9% | 247 | +12.6% |
| Operating profit (EBITDA) | 102 | 98 | +4.1% | 91 | +12.1% |
| Operating margin | 37% | 40% | -3 pp | 37% | 0 pp |
| Profit before tax | 90 | 99 | -9.1% | 86 | +4.7% |
| Net profit (PAT) | 68 | 74 | -8.1% | 63 | +7.9% |
| EPS (₹) | 3.24 | 3.54 | -8.5% | 3.01 | +7.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹312 Cr, net profit ₹76 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Concord Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Concord Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Concord Biotech Ltd Q3 FY26 results?
FY '26 growth expected below historical averages due to first-half challenges; optimistic for Q4 improvement. FY '26 growth expected below historical averages due to H1 challenges but Q3 & Q4 show improving momentum.
What is Concord Biotech Ltd share price analysis?
Concord Biotech Ltd currently shows a neutral. The stock trades at a P/E of 51.0 with a market cap of ₹14,489 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Concord Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
